Celldex Therapeutics, Inc. (CLDX) — Stock Price, Chart & Analysis
Celldex Therapeutics, Inc. (CLDX) is a Healthcare stock currently trading at $33.51, up 0.30% on the day. It carries a market capitalization of $2.63B. Over the past 52 weeks, CLDX has traded between $22.10 and $45.14. Celldex Therapeutics, Inc. does not currently pay a regular dividend. View the live CLDX chart, technical opinion, analyst ratings, fundamentals and latest news below.
Celldex Therapeutics, Inc. (CLDX) key data
| Price | $33.51 |
| Change (today) | +0.30% |
| Previous close | $33.41 |
| Market cap | $2.63B |
| EPS (TTM) | $-3.85 |
| 52-week high | $45.14 |
| 52-week low | $22.10 |
| Beta | 0.84 |
| Avg. volume | 991.5K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Celldex Therapeutics, Inc. (CLDX)
How much does one share of Celldex Therapeutics, Inc. cost?
As of the latest update, one share of Celldex Therapeutics, Inc. (CLDX) trades at $33.51 (+0.30% today).
What is Celldex Therapeutics, Inc.'s market cap?
Celldex Therapeutics, Inc. has a market capitalization of approximately $2.63B.
What is Celldex Therapeutics, Inc.'s earnings per share (EPS)?
Celldex Therapeutics, Inc.'s trailing twelve-month EPS is $-3.85.
Does Celldex Therapeutics, Inc. pay a dividend?
Celldex Therapeutics, Inc. does not currently pay a regular dividend.
What is Celldex Therapeutics, Inc.'s 52-week trading range?
Over the past year, CLDX has traded between $22.10 and $45.14.
What is the analyst price target for Celldex Therapeutics, Inc.?
The mean analyst price target for Celldex Therapeutics, Inc. is $61.93. This is informational only and not investment advice.
Latest Celldex Therapeutics, Inc. (CLDX) news
- CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’News · Sep 22, 2026
- Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable ResponsesNews · Sep 22, 2026
- Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 TrialsNews · Sep 22, 2026
- Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria TrialsNews · Sep 22, 2026
- Celldex to Present at Upcoming Investor ConferenceNews · Sep 8, 2026
- Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter ResultsNews · Aug 9, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live CLDX dashboard…